利用CODEFACS与LIRICS从 bulk 基因表达中解卷积临床相关细胞免疫互作,将黑色素瘤患者分层至抗PD-1治疗
研究开发CODEFACS工具从bulk表达数据解卷积各细胞类型特异性基因表达,并开发LIRICS统计框架优先筛选临床相关配体-受体互作。CODEFACS优于CIBERSORTx;在TCGA中揭示与错配修复缺陷相关的细胞类型特异性配体-受体互作;在黑色素瘤微环境中识别出比部分近期bulk转录组方法更好地分层抗PD-1治疗患者生存的互作。
要点
- CODEFACS解卷积性能优于CIBERSORTx。
- TCGA分析发现与错配修复缺陷相关的细胞类型特异性配体-受体互作。
- 黑色素瘤TME中部分配体-受体互作对抗PD-1治疗生存的分层优于部分bulk转录组方法。
核心结论
- 研究提出CODEFACS和LIRICS两种计算方法,可解卷积bulk肿瘤基因表达为细胞类型特异性表达谱,并识别预测免疫检查点阻断治疗反应的细胞类型特异性配体-受体互作。
研究设计与样本
- 研究开发CODEFACS工具从每个样本的bulk表达中解卷积细胞类型特异性基因表达,并开发LIRICS统计框架从解卷积数据中优先筛选细胞类型间临床相关配体-受体互作。
- 研究首先比较CODEFACS与当前最优解卷积方法CIBERSORTx的性能。
- 研究分析癌症基因组图谱(TCGA)数据,并在黑色素瘤肿瘤微环境中识别配体-受体互作。
主要发现
- CODEFACS在解卷积性能上优于CIBERSORTx。
- 在TCGA分析中,研究揭示与错配修复缺陷相关的细胞类型特异性配体-受体互作,这些互作在不同癌症类型中独特关联,为错配修复缺陷肿瘤相比其他高新抗原负荷肿瘤对抗程序性细胞死亡蛋白1(PD-1)治疗敏感性增强提供额外见解。
- 研究在黑色素瘤TME中识别出一组细胞类型特异性配体-受体互作,其对抗PD-1治疗患者生存的分层优于部分近期发表的bulk转录组学方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. To discover such interactions, we developed CODEFACS (COnfident DEconvolution For All Cell Subsets), a tool deconvolving cell type-specific gene expression in each sample from bulk expression, and LIRICS (Ligand-Receptor Interactions between Cell Subsets), a statistical framework prioritizing clinically relevant ligand-receptor interactions between cell types from the deconvolved data. We first demonstrate the superiority of CODEFACS versus the state-of-the-art deconvolution method CIBERSORTx. Second, analyzing The Cancer Genome Atlas, we uncover cell type-specific ligand-receptor interactions uniquely associated with mismatch-repair deficiency across different cancer types, providing additional insights into their enhanced sensitivity to anti-programmed cell death protein 1 (PD-1) therapy compared with other tumors with high neoantigen burden. Finally, we identify a subset of cell type-specific ligand-receptor interactions in the melanoma TME that stratify survival of patients receiving anti-PD-1 therapy better than some recently published bulk transcriptomics-based methods. SIGNIFICANCE: This work presents two new computational methods that can deconvolve a large collection of bulk tumor gene expression profiles into their respective cell type-specific gene expression profiles and identify cell type-specific ligand-receptor interactions predictive of response to immune-checkpoint blockade therapy. This article is highlighted in the In This Issue feature, p. 873.
引用
- Wang K, Patkar S, Lee JS, et al. Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti-PD-1 Therapy. Cancer Discov. 2022. PMID: 34983745. doi:10.1158/2159-8290.CD-21-0887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。